AU2023206381A1 - Method of administering upadacitinib to avoid adverse drug interactions and effects - Google Patents

Method of administering upadacitinib to avoid adverse drug interactions and effects Download PDF

Info

Publication number
AU2023206381A1
AU2023206381A1 AU2023206381A AU2023206381A AU2023206381A1 AU 2023206381 A1 AU2023206381 A1 AU 2023206381A1 AU 2023206381 A AU2023206381 A AU 2023206381A AU 2023206381 A AU2023206381 A AU 2023206381A AU 2023206381 A1 AU2023206381 A1 AU 2023206381A1
Authority
AU
Australia
Prior art keywords
upadacitinib
patients
dose
daily
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023206381A
Other languages
English (en)
Inventor
Mohamed-Eslam F. Mohamed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of AU2023206381A1 publication Critical patent/AU2023206381A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023206381A 2022-01-13 2023-01-13 Method of administering upadacitinib to avoid adverse drug interactions and effects Pending AU2023206381A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263299324P 2022-01-13 2022-01-13
US63/299,324 2022-01-13
US202263320149P 2022-03-15 2022-03-15
US63/320,149 2022-03-15
PCT/US2023/060648 WO2023137440A2 (en) 2022-01-13 2023-01-13 Method of administering upadacitinib to avoid adverse drug interactions and effects

Publications (1)

Publication Number Publication Date
AU2023206381A1 true AU2023206381A1 (en) 2024-07-25

Family

ID=87279802

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023206381A Pending AU2023206381A1 (en) 2022-01-13 2023-01-13 Method of administering upadacitinib to avoid adverse drug interactions and effects

Country Status (8)

Country Link
US (1) US20230233555A1 (https=)
EP (1) EP4463161A4 (https=)
JP (1) JP2025502266A (https=)
KR (1) KR20240148324A (https=)
AU (1) AU2023206381A1 (https=)
CA (1) CA3246767A1 (https=)
MX (1) MX2024008557A (https=)
WO (1) WO2023137440A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12570664B2 (en) 2015-10-16 2026-03-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11564922B2 (en) * 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
AU2018230500B2 (en) * 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis
US10857144B2 (en) * 2017-05-16 2020-12-08 Bow River LLC Methods of treatment

Also Published As

Publication number Publication date
WO2023137440A3 (en) 2023-10-05
EP4463161A2 (en) 2024-11-20
EP4463161A4 (en) 2026-01-14
MX2024008557A (es) 2024-09-11
CA3246767A1 (en) 2023-07-20
JP2025502266A (ja) 2025-01-24
US20230233555A1 (en) 2023-07-27
KR20240148324A (ko) 2024-10-11
WO2023137440A2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
US20230233555A1 (en) Method of administering upadacitinib to avoid adverse drug interactions and effects
JP2026001038A (ja) 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤
HK1226940A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
KR20240162066A (ko) 미르다메티닙을 이용한 피부 신경섬유종 치료
US20250262193A1 (en) Therapeutic Tyrosine Kinase Inhibitors For Multiple Sclerosis and Myasthenia Gravis
US8957071B2 (en) Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
TWI879737B (zh) 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法
JP2018118914A (ja) 神経変性疾患の改善用医薬
JP2023522623A (ja) 全身性過炎症反応を伴う状態の処置に使用するエクリタセルチブ
Uchiyama et al. Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies
Chen et al. Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection
AM et al. Full prescribing information
DK2686004T3 (en) COMPOSITION COMPREHENSIVE DIAMINOXIDASE TO USE FOR TREATMENT OR PREVENTION OF FIBROMYALGY OR CHRONIC TIRE SYNDROME
KR20200021479A (ko) 페마피브레이트를 함유하는 의약
CN118891046A (zh) 施用乌帕替尼以避免不良药物相互作用和反应的方法
JP6042886B2 (ja) 早漏症治療用の薬学組成物
AB Summary of product characteristics
US12409172B2 (en) Dosage regimen
US20260060974A1 (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis
US20240238290A1 (en) Use of complement factor d inhibitor for treatment of generalized myasthenia gravis
Baker Approvals, submission, and important labeling changes for US marketed pharmaceuticals
Pandit et al. PRINCIPLES AND SCIENTIFIC BASIS OF HIV THERAPY
WO2026050513A1 (en) Tolebrutinib for multiple sclerosis
KR20250084183A (ko) 다발성 경화증에 대한 치료용 티로신 키나제 저해제
Ramezaninejad et al. The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial